George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
https://www.bioworld.com/articles/432927-hong-kong-researchers-create-fastest-coronavirus-diagnostic-test-to-date
Warning: This isn't a de-ramp....
Interesting to see that a HK company appear to have released a test that can provide results in 40 minutes and already have CE Mark approval. Have no idea on the size or team behind it. Just thought it's relevant that tests and technology is improving, hope we can stay ahead of the curve. Certainly the best option in the UK right now.
Well we know they've been in touch with Andrew Scott TV regarding an interview so they must have something else to talk about rather than the Sheikh Lock-In Agreement RNS.
I think we will get the update most are craving this week. It won't be the full hog funding agreement but I imagine it'll be an operational update / corporate update. That will provide them with the opportunity to discuss the companies new strategy moving forward, the appointment of new PR/Marketing firm, update on Block VI developments etc.
In all honesty, however ridiculous it sounds I imagine there has been some form of hold up at China Coal due to the Corona Virus. It's a very real possibility.
That's it exactly Jarv55. I am trying to find information.
Investors here can't seem to grasp my point that if after researching competitors the evidence points to the fact we are in fact quicker, cheaper and clearly ahead of the game... then great!
The biggest benefit for us at present isn't as much FDA approval or the CE Mark but the fact we are potentially aligned with PHE and NHS. The only other UK Biotech I can find information on is an organisation called Genefirst.
They issued a press release on 3rd February stating they have produced two kits, one for the 2019 strain (so not as unique to NCYT as first thought) and one kit that identifies 17 other viruses to avoid mis-diagnosis.
I have no idea if they are in anyway a threat to NCYT NHS contracts, who knows there might be a potential JV possibility to tackle this together? For those interested the link is below. *Awaits de-ramper abuse...
https://www.genefirst.com/copy-of-innovate-shanghai-grant
If it transpires that many others are seeking FDA approval (35 number reported yesterday but haven't seen facts of this) then so be it.
I can see how this may be portrayed as negative, but really I'm just trying to understand if what we have is as good as I want it to be!
Some right numpties on here. It appears you can't post anything that goes against your agenda of pump pump pump. I've made it pretty clear, I am holding. I believe its great short term investment.
Maybe some constructive conversation around our product and it's benefits / limitations / competitors products would actually HELP the SP. But why would you want to research?
I'll leave you to it.
Not at all. I hold a large holding here. Negative spin if you want to read it that way. Up to you.
I didn't see the information in the week regarding competitors. The link I shared was from 6th February.
The Times article is wrong by the way. No vaccine being manufactured by Novacyt, tests only. Might want to change the thread title.
I just find it interesting that as soon as I mention the word competition everyone is quick to jump on it and label me as a de-ramper. It could be seen as the opposite, if the competition is weaker than us.
Understanding your direct and indirect competition is key to any successful business. Surely everyone can see how that is a valid point to make.
I'll leave it at that as clearly people don't want to understand how research of our competition could have an impact on the SP. Both positive and negative.
If you read my posts you will see I am not worried... Instead I simply said they would be good to research so we can build a picture if what we have developed is unique or easily replicated. The RNS released to date hint towards the fact that are test is different to others. Rather than just accept this it's useful to understand if others, especially those closer to us in the EU are producing similar testing kits.
I suppose some of you don't understand the concept of research.
You will also see that I said this a good short term investment IMO. Be honest how many of you will still be here if this reaches £1.
The times article that references a 'vaccine' for validation purposes is meant to be the word 'tests'. The text was taken direct from the RNS.
If I was you I'd ask the journo to clarify before you start posting that a "leak" has been printed...
It's called research. They are long posts because I'm copying and pasting from a link.
You'd be kidding yourself if you're not concerned about the competition our there. Every smart investor should know what their competitors are doing. If you want to believe that we are the best and nobody else can do what we can do then that's up to you and is very short sighted.
Personally I feel we have a big part to play in the early development of this (hence why I said it's a short term investment) but as things develop its likely bigger fish will come into play. It's how the world works.
Weekend de-ramper, Jesus wept.
I should add to be fair the numbers aren't great as things stand but I understand the reasoning for this is purely based on demand and the fact that this is a new product.
Not to say we can't make money on our investment here but the biggest concern on many investors minds when the first RNS came out was the competition. It doesn't matter if you're first. What matters is who can meet the supply and demand. At present 33,000 kits sold aren't great numbers.
Looking at the list of EU companies alone and the plethora of companies in the US already pending FDA approval I struggle to see long term how we are going to end up as major players in all of this. Short term, make a few quid, long term there are bigger fish in the ocean.
UK based company is called GeneFirst (Oxford, UK) — developing two test kits; a three-hour PCR-based test for 2019-nCoV, and a multiplex PCR assay for 2019-nCoV as well as 17 other common viruses and bacteria.
The List of companies from that link is too large to paste in here so I've just copied the ones from the EU below. Rest on the list were US and Korean / China based.
Would be good to research these in particular and see how they compare to ours.
Ares Genetics (Vienna, Austria) - BGI has since begun a collaboration with Curetis and its subsidiary Ares Genetics to develop a sequencing-based test and to distribute BGI's PCR-based test in Europe.
Patients with suspected 2019-nCoV infection in China appear to have been tested primarily using a real-time fluorescent RT-PCR kit from BGI which recently received emergency authorization from China's National Medical Products Administration. BGI has donated 20,000 kits to support the response to the 2019-nCoV outbreak in Wuhan, China and Hubei Province, where the outbreak originated, and provided about 50,000 test kits in total to hospitals and disease control centers in China.
Altona Diagnostics (Hamburg, Germany) — developing a real-time RT-PCR based assay for the qualitative detection of 2019-nCoV RNA in respiratory samples.
CerTest (Zaragoza, Spain) — developing a test kit called VIASURE 2019-nCoV Real Time PCR Kit, based on its existing qPCR tests for other coronaviruses.
Genekam Biotechnology (Duisburg, Germany) — developed singleplex and multiplex test kits to detect 2019-nCoV as well as to distinguish it from other infections, such as influenza, MERS, and viruses commonly found in bats.
Genomica (Madrid) — developing a 2019-nCoV diagnostic kit to simultaneously analyze 96 patient samples in less than five hours, to be available in five to seven weeks, using the firm's low-density microarray-based platform. Genomica has also had a subsidiary in Wuhan, China, named HuaSin Science, since January 2018.
Roche Diagnostics (Basel, Switzerland) — the firm has partnered with Tib-Molbiol to launch three research-use-only assays for the LightCycler 480 high-throughput real-time PCR instrument, as previously reported.
Other firms developing methods to detect or diagnose the coronavirus include Oxford Nanopore, a team of European virologists who pioneered the test protocol guided for use by the World Health Organization, and Co-Diagnostics, as previously reported.
Atila Biosystems is also reportedly working to develop a test using its high-throughput isothermal nucleic acid amplification system.
I don't disagree but the CEO clearly stated that the fact we are able to test only the 2019 strain sets us apart from others isn't the case. There are plenty others by the looks of it.
21 on the list. 6 of which are EU based.
I would like to understand why they would chose ours. Do we differ to others or have they simply produced a similar product?
This is not a de-ramp. I am invested. I would just like to understand more.
In terms of the NHS I agree, this should be a contract we have tied up as we were firs to market. But with little demand at present in the UK it's difficult to understand the potential of the size and value it can being.
--- CORRECT LINK ---
https://www.genomeweb.com/pcr/worries-grow-over-novel-coronavirus-dx-industry-jumps-action#.Xj24aTjLfqs
As you can see plenty of others and I want to understand what makes us different.
Also an Oxford based organisation on the list. Plenty in the US which would surely be looking for FDA approval?
Understandable we are not alone in tackling this but I didn't quite expect so many other biotechs to be producing testing kits for the 2019 strain ...
Need the CEO to clarify as there are plenty of EU and US based organisations on the list....
https://www.bioworld.com/articles/432890-coronavirus-outbreak-pushes-chinese-biotech-stocks-higher-despite-market-downturn
What sets NCYT apart from the competitors identified below??
https://www.bioworld.com/articles/432812-novacyt-launches-test-for-new-coronavirus
Race to develop tests
Other companies are rushing to meet the demand for coronavirus testing as well. On Jan. 28, Salt Lake City-based Co-Diagnostics Inc. reported that it had successfully completed initial verification of an assay to screen for the presence of 2019-nCoV and would be ready to begin distributing its tests to affected markets soon.
Also last week, Austrian diagnostics company Ares Genetics GmbH announced a collaboration with BGI Group to make molecular tests for the new coronavirus available in Europe. The next-generation sequencing service will use BGI reagents. BGI has developed a real-time fluorescence PCR kit for detecting the strain, which produces results in several hours. The test kit has been approved by China’s National Medical Products Administration, and BGI said it has shipped about 50,000 kits to hospitals and disease control centers in China.
Also in the game is Cincinnati-based Meridian Bioscience Inc. The company recently touted its molecular diagnostic test in detecting 2019-nCoV. “The advantage of the Meridian Lyo-Ready 1-Step RT-qPCR Mix is that the assay can be set up and freeze-dried, so that they are highly stable, just requiring the patient sample to be added and the assay run,” said Liang Zhang, general manager for Meridian in China. “This means that patients can be screened very quickly to help stop the spread of the virus.”
Other companies still are monitoring the situation. In a roundup of comments on the potential impact of the coronavirus, released by Wells Fargo analyst Larry Biegelsen, Becton Dickinson said it is doing what it can to support those on the front lines of the crisis. “While BD does not have an official diagnostic test for the coronavirus, we have seen a number of additional orders in the last few weeks for our BD Max molecular system in China as it is an open system and local officials are looking to develop their own content to run tests.” The uptick is not expected to have a significant impact on business.
https://www.bioworld.com/articles/432812-novacyt-launches-test-for-new-coronavirus
Novacyt is currently making the test available to laboratories as a research use-only assay throughout its sales channels, and has seen strong, early demand from more than 10 countries. As for broader availability, the company is still determining the best route forward.
“In the event a manufacturer pursued full regulatory approval for clinical use, it could take six months or more with regulators such as the FDA,” he said. “There is an emergency use process with most regulators, and this might reduce the time for a limited approval within weeks, depending upon the criteria the regulators require.
The UK is now one of the first countries outside China to have a prototype specific laboratory test for this new disease. Healthcare professionals who are contacted by a patient with symptoms following travel to Wuhan have been advised to submit samples to PHE for testing. Individuals should be treated in isolation
......
When a clinician suspects novel coronavirus (2019-nCov), they take samples from the nose, throat and deeper respiratory samples, package and send them safely to PHE Colindale. PHE can provide a laboratory result from this specific virus on the same working day.
PHE also has the capability to sequence the viral genome and compare this to published sequences from China, if a case occurs. This will provide valuable information on any mutations in the virus over time and allow an improved understanding of how it spreads.
I'll be honest, by now I really did expect another EU organisation to have come out with an alternative.
It appears that is not the case...
In fact it is the opposite, with Spain and Portugal both releasing news yesterday stating the Primer Design name (our kit)
We have had the BBC in to interview.
The company have been at a week long show promoting to various medical professionals. I can imagine this was very popular.
Orders based in the last RNS were at 10,000 ... Can't wait to see the numbers in the next one.
Even if there's no mention of the NHS this is still capable of many many times it's Mcap.
Hold on a few days. 0.85 my first target here.